Skip links
Vision Life Sciences

Oncology and Biologics: Driving Global Biopharma Deals

As we look back on 2023 from our vantage point in 2024, it’s clear that oncology and biologics continued to dominate the landscape of global biopharma partnerships. Our latest research at Vision Lifesciences reveals that these sectors not only led in deal-making activities but also set new benchmarks for investment and collaboration across the industry.


Oncology: Maintaining Its Powerhouse Status

Cancer therapies remained at the forefront of biopharma deals in 2023, with total deal values reaching an impressive $86.1 billion. This figure significantly outpaced other therapeutic areas, underscoring the industry’s continued focus on addressing the global cancer burden.

Several high-profile collaborations exemplified this trend:

-Daiichi Sankyo and Merck’s landmark deal, announced in October 2023, stood out with its $4 billion upfront payment and a potential total value of $22 billion. This collaboration, focusing on three antibody-drug conjugate (ADC) programs, showcases the industry’s confidence in the potential of targeted cancer therapies.
-AbbVie’s acquisition of ImmunoGen for $10.1 billion in November 2023 further highlighted the appeal of ADC technology in oncology. This deal gave AbbVie access to Elahere, an FDA-approved ADC for ovarian cancer.
-Pfizer and Seagen’s $43 billion merger, announced in March 2023, represented another major move in the oncology space, combining Pfizer’s resources with Seagen’s expertise in ADCs.


Biologics: The Cornerstone of Innovation

Alongside oncology, biologics and complex molecules emerged as key drivers of deal activity. These advanced therapeutics, including antibodies, proteins, and nucleic acid-based treatments, accounted for $80.3 billion in total deal value in 2023.
The surge in interest for antibody-drug conjugates (ADCs) was particularly notable:

The aforementioned Daiichi Sankyo-Merck deal centered on ADC technology.
Collaborations like those between Takeda and Turnstone Biologics, and between Bristol Myers Squibb and Tubulis, further underscore the industry’s focus on ADCs.


Beyond ADCs, other biologic modalities also saw significant activity:

-Regeneron and Intellia Therapeutics expanded their collaboration in gene editing and therapy, with a $70 million upfront payment.
-Vertex Pharmaceuticals acquired ViaCyte for $320 million, bolstering its cell therapy pipeline for type 1 diabetes.


Market Implications and Future Outlook

The dominance of oncology and biologics in 2023’s deal-making reflects the industry’s commitment to addressing areas of high unmet medical need with cutting-edge technologies. For pharmaceutical and biotech companies, this trend underscores the importance of building strong pipelines in these areas, either through internal development or strategic partnerships.

As we progress through 2024, we anticipate continued strong interest in oncology and biologics. However, companies should also be alert to emerging areas that could rapidly gain traction:

Neurodegenerative diseases: With Eisai and Biogen’s success in Alzheimer’s treatment, we expect increased activity in this space.
Rare genetic disorders: The success of gene therapies like bluebird bio’s Zynteglo may spur more deals in this area.
Immunology and inflammation: As seen with the continued success of drugs like Humira and its biosimilars, this remains a key area of interest.


The Complex Landscape of Cross-Border Collaborations

It’s worth noting that many of 2023’s significant deals involved cross-border collaborations, particularly between Asian and Western companies. This trend highlights the increasingly global nature of biopharma innovation and the importance of navigating different regulatory and cultural landscapes.

As the biopharma landscape continues to evolve, staying informed about these trends is crucial for companies looking to make strategic decisions about their pipelines, partnerships, and investment focus. The complex nature of these deals, particularly in cross-border collaborations, often necessitates specialized expertise to navigate successfully.

In conclusion, oncology and biologics are not just leading the way in biopharma deals; they are shaping the future of the industry. As we move through 2024 and beyond, these sectors will likely continue to be pivotal in driving innovation and creating value in the global life sciences ecosystem. Companies that can successfully navigate this landscape, forging strategic partnerships and leveraging cutting-edge technologies, will be well-positioned to make significant impacts in patient care and achieve commercial success.

Leave a comment